Health economic study shows positive outcome using Integrum’s OPRA[TM] Implant System over socket prostheses in transfemoral amputees
Mölndal, Sweden – March 19, 2024 — Integrum (publ) (Nasdaq First North Growth Market: INTEG B) announces that a team of independent researchers, from six prestigious academic and clinical institutions in the US, have published a health economic article analyzing potential effects on societal cost-control and quality-of-life when utilizing osseointegrated transfemoral prostheses compared to traditional socket prostheses. The study’s meta-analyses show that costs associated with maintaining functional socket prosthesis usage exceed those of using osseointegration alternatives several times while simultaneously improving quality of life. The article will be featured in the March 2024 issue of Bone & Joint Open.
In summary, the results from the recently published meta-study point toward improved quality in life as well as positive societal cost-control outcomes in cases where physically active transfemoral amputees receive the OPRA™ Implant System. Based on these new insights, Integrum will be able to provide more effective data in conversations with representatives from paying institutions in the US.
The aim of the current study was to use a disease-specific quality of life (QoL) instrument, more accurate in reflecting a patient’s QoL, and produce a fair cost-effectiveness evaluation of the OPRA™ Implant System. Compared to previous studies, the new data consider longer-term (5-to-15-year) outcomes, providing new insights into the longevity, mechanical complications, and patient-reported outcomes following OPRA™ Implant System. The study, therefore, fills an important knowledge gap where previous studies have presented fractured evaluations on costs, quality of life, or the cost-effectiveness of osseointegration versus traditional socket prostheses.
“We are glad to take part in these new important results that point clearly toward the positive effects on both quality of life for the individual patients, as well as the societal benefits of the OPRA™ Implant System. By providing long-term and disease-specific evaluations for our treatment alternative, we’re presented with new opportunities to enter discussions with institutions that oversee the financial structure of healthcare providers,” says Rickard Brånemark, CEO of Integrum.
The article is based on a joint study by researchers from Walter Reed National Medical Center, Ohio State University Wexner Medical Center, Johns Hopkins University, University of Colorado School of Medicine, Atrium Health, and the Mayo Clinic.
To read the full article, follow the link: Lifetime cost-effectiveness analysis osseointegrated transfemoral versus socket prosthesis using Markov modelling.
For more information, please contact:
Rickard Brånemark, CEO
Phone: +46 (0) 70 846 10 61
E-mail: rickard.branemark@integrum.se
Jörgen Svanström, CFO
Phone: + 46 (0) 70 734 96 60
E-mail: Jorgen.svanstrom@integrum.se
Certified Adviser
Carnegie Investment Bank AB (publ) is Certified Adviser.